Can a new pill tame ulcerative colitis Flare-Ups?

NCT ID NCT07755241

Not yet recruiting Disease control Sponsor: Accro Bioscience (Suzhou) Limited Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This clinical trial is testing an experimental oral medication called AC-101 in adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease. The study aims to see if AC-101 can help achieve clinical remission—meaning fewer symptoms and healed intestinal lining—compared to a placebo. Participants will take either a high dose, low dose, or placebo tablet twice daily for 12 weeks, with an optional extension period. The trial is for people who have not responded well to prior treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AC-101 tablets (an experimental oral drug)
What this could lead to: If successful, AC-101 could offer a new oral treatment option for people with ulcerative colitis who haven't responded to other therapies.
What could go wrong: This is an early-stage (Phase 2b) trial, so the drug may not prove effective or safe. Results from this small study will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.